Experiments from Hutzler et al. (2017) show increased antigen-specific immunity and anti-CLDN6 antibody production when the B16-F10 melanoma cell line was treated with recombinant measles virus-encoded with the CLDN6 gene. The gene discussed is CLDN6; the disease is melanoma.